Literature DB >> 6114281

Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin.

F D Dastur, V P Awatramani, S K Dixit, J A D'Sa, N D Cooverji, M P Anand.   

Abstract

Tests among 410 Indians not artificially immunised against tetanus showed that 80% had measurable antitoxin. Single doses (100 Lf or 250 Lf) of a potent tetanus toxoid were given to such individuals with naturally acquired antitoxin. The 100 Lf dose produced on average a ten-fold rise in antibody level, and the 250 Lf dose a twenty-fold rise. In adults who had been artificially immunised, a 5 Lf dose produced a four-fold to ten-fold rise in antibody level. In infants three doses of triple vaccine produced satisfactory antitoxin concentrations. The levels of antibody achieved after a single 250 Lf dose should protect for 5 years. Single-dose vaccination may be better than the conventional three-dose scheme for a population that is unlikely to comply with a three-dose regimen and in whom naturally acquired antitoxin is associated with partial tolerance to tetanus toxoid. Naturally acquired antitoxin in Indians is probably the result of chronic clostridial contamination of the small bowel. This contamination can induce immune tolerance in the gut and systemically and may be the reason for the poor responses to vaccination in all except infants.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114281     DOI: 10.1016/s0140-6736(81)90472-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Naturally acquired immunity to tetanus toxin in an isolated community.

Authors:  H Matzkin; S Regev
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

2.  Single dose tetanus toxoid--a review of trials in India with special reference to control of tetanus neonatorum.

Authors:  K Agrawal; K Pandit; A T Kannan
Journal:  Indian J Pediatr       Date:  1984 May-Jun       Impact factor: 1.967

Review 3.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

4.  Control of neonatal tetanus.

Authors:  A M Galazka
Journal:  Indian J Pediatr       Date:  1985 Jul-Aug       Impact factor: 1.967

Review 5.  Tetanus in Ethiopia: unveiling the blight of an entirely vaccine-preventable disease.

Authors:  Yohannes Woubishet Woldeamanuel
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

6.  Study of anti tetanus IgG and IgM levels in maternal and cord sera by enzyme linked immunosorbent assay (ELISA).

Authors:  S Sundar; N Wagle; B L Varudkar; A Vaidya; S M Merchant
Journal:  Indian J Pediatr       Date:  1990 Nov-Dec       Impact factor: 1.967

7.  Neonatal tetanus in Peru: risk assessment with modified enzyme-linked immunosorbent assay and toxoid skin test.

Authors:  L Vernacchio; G Madico; M Verastegui; F Diaz; T S Collins; R H Gilman
Journal:  Am J Public Health       Date:  1993-12       Impact factor: 9.308

8.  Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis.

Authors:  D J Balestra; B Littenberg
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

9.  Veal Calves Produce Less Antibodies against C. Perfringens Alpha Toxin Compared to Beef Calves.

Authors:  Bonnie R Valgaeren; Bart Pardon; Evy Goossens; Stefanie Verherstraeten; Sophie Roelandt; Leen Timbermont; Nicky Van Der Vekens; Sabrina Stuyvaert; Linde Gille; Laura Van Driessche; Freddy Haesebrouck; Richard Ducatelle; Filip Van Immerseel; Piet Deprez
Journal:  Toxins (Basel)       Date:  2015-07-10       Impact factor: 4.546

Review 10.  A rare case of type 1 leprosy reactions following tetanus infection in a borderline tuberculoid leprosy patient and a literature review.

Authors:  Chao Shi; Zhi-Chun Jing; De-Gang Yang; Jian-Yu Zhu
Journal:  Infect Dis Poverty       Date:  2018-06-17       Impact factor: 4.520

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.